Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Iloperidone Tablets (Fasting & Postprandial)
NCT03420534Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iloperidone in schizophrenia (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Plasma Concentration at 120 hours, Time to Maximum Concentration at 120 hours and 5 more. Status: unknown.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03420534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420534.